4 completed, 1 terminated, 1 unknown. 4 Phase 1, 2 Phase 2.
By phase and status
Follow Metatropic dwarfism: new trials by email Literature Review of Metatropic dwarfism trials Research Report on Metatropic dwarfism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
CC-90010, Temozolomide, Radiotherapy - Glioblastoma | Phase 1 | Terminated | Celgene | 184 | 2020-07-10 | 2024-07-26 |
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
Everolimus - Neuroendocrine Tumors | Phase 1 / Phase 2 | Unknown | King Faisal Specialist Hospital & Research Center | 30 | 2012-12-01 | 2018-08-14 |
A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males
ASP8477, omeprazole, Placebo - Pharmacokinetics of ASP8477, Pharmacodynamics of ASP8477 | Phase 1 | Completed | Astellas Pharma Europe B.V. | 72 | 2010-11-01 | 2014-08-20 |
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule) - Solid Tumors | Phase 1 | Completed | Genzyme, a Sanofi Company | 87 | 2009-07-01 | 2014-03-19 |
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Cilengitide, Cetuximab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 232 | 2009-02-01 | 2017-01-13 |
Retrospective Analysis of De-identified Deceased HCC Patients
Survival | | Completed | Carr, Brian | 1000 | 1995-06-01 | 2023-07-27 |
Narrower conditions
Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Neoplasms (1) · Neuroendocrine Tumors (1)
Broader conditions
Neoplasms (3) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Astrocytoma (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Glioma (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Neuroepithelial (1) · Respiratory Tract Diseases (1)
Interventions
ASP8477 (1) · Cetuximab (1) · Cilengitide (1) · Cisplatin (1) · Drug Therapy (1) · Everolimus (1) · Gemcitabine (1) · Genz-644282 (1) · Omeprazole (1) · Radiotherapy (1) · Temozolomide (1) · Vinorelbine (1)
Sponsors
Astellas Pharma Europe B.V. (1) · Carr, Brian (1) · Celgene (1) · Genzyme, a Sanofi Company (1) · King Faisal Specialist Hospital & Research Center (1) · Merck KGaA, Darmstadt, Germany (1)
Countries
Belgium (2) · France (2) · Italy (2) · Spain (2) · United States (2) · Czechia (1) · Denmark (1) · Germany (1) · Ireland (1) · Netherlands (1) · Norway (1) · Poland (1) · Saudi Arabia (1) · Sweden (1)
Top investigators
Ali Aljubran, MD (1) · Fazal Hussain, MD (1)
Results publications
PMID 25939894, PMID 36455228
NIH funding
2009 (1), 2019 (1)